<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04147494</url>
  </required_header>
  <id_info>
    <org_study_id>19-000756</org_study_id>
    <secondary_id>NCI-2019-07265</secondary_id>
    <secondary_id>19-000756</secondary_id>
    <nct_id>NCT04147494</nct_id>
  </id_info>
  <brief_title>Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues</brief_title>
  <official_title>PET Biodistribution Study of 68Ga-PSMA-11 and 68Ga-FAPI-46 in Patients With Non-Prostate Cancers: An Exploratory Biodistribution Study With Histopathology Validation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies a new imaging technique called FAPi PET/CT to determine where and&#xD;
      to which degree the FAPI tracer (68Ga-FAPi-46) accumulate in normal and cancer tissues in&#xD;
      patients with non-prostate cancer. The research team also want to know whether what they see&#xD;
      on PET/CT images represents the tumor tissue being excised from the patient's body. The&#xD;
      research team is also interested to investigate another new imaging technique called PSMA&#xD;
      PET/CT. Participants will be invited to undergo a second PET/CT scan, with the PSMA tracer&#xD;
      (68Ga-PSMA-11). This is not required but just an option for volunteer patients. Patients can&#xD;
      decide to have only the FAPI PET/CT scan. The PET/CT scanner combines the PET and the CT&#xD;
      scanners into a single device. This device combines the anatomic (body structure) information&#xD;
      provided by the CT scan with the metabolic information obtained from the PET scan. PET is an&#xD;
      established imaging technique that utilizes small amounts of radioactivity attached to very&#xD;
      minimal amounts of, in the case of this research, 68Ga-PSMA-11 and 68Ga-FAPi. Because some&#xD;
      cancers take up 68Ga-PSMA-11 and/or 68Ga-FAPi it can be seen with PET. CT utilizes x-rays&#xD;
      that traverse the body from the outside. CT images provide an exact outline of organs where&#xD;
      it occurs in patient's body. FAP stands for Fibroblast Activation Protein. FAP is produced by&#xD;
      cells that surround tumors. The function of FAP is not well understood but imaging studies&#xD;
      have shown that FAP can be detected with FAPI PET/CT. Imaging FAP with FAPI PET/CT may in the&#xD;
      future provide additional information about various cancers. PSMA stands for Prostate&#xD;
      Specific Membrane Antigen. This name is incorrect as PSMA is also found in many other&#xD;
      cancers. The function of PSMA is not well understood but imaging studies have shown that PSMA&#xD;
      can be detected with PET in many non-prostate cancers. Imaging FAP with PET/CT may in the&#xD;
      future provide additional information about various cancers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To define the biodistribution of gallium Ga 68 FAPi-46 (68Ga-FAPi-46) and gallium Ga&#xD;
      68-labeled PSMA-11 (68Ga-PSMA-11) in normal and cancer tissues of patients with various&#xD;
      non-prostate malignancies. The goal is to determine where and to which degree 68Ga-FAPi-46&#xD;
      and 68Ga-PSMA-11 accumulates in normal and cancer tissues.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate whether 68Ga-FAPi-46 and 68Ga-PSMA-11 accumulation observed by positron&#xD;
      emission tomography (PET) correlates with the amount of fibroblast activation protein (FAP)&#xD;
      and prostate specific membrane antigen (PSMA) in excised cancer tissue, respectively.&#xD;
&#xD;
      II. As an exploratory study aim, will also assess the 68Ga-FAPI-46 biodistribution&#xD;
      correlation with 68Ga-PSMA-11, if the patient volunteers for optional scan, and&#xD;
      18F-fluodeoxyglucose (FDG), if any FDG PET/computed tomography (CT) has been performed as&#xD;
      standard-of-care.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive 68Ga-FAPi-46 intravenously (IV) and undergo PET/CT scan over 20-50 minutes.&#xD;
      Patients may also receive 68Ga-PSMA-11 IV and undergo PET/CT scan over 20-50 minutes on a&#xD;
      separate day (for volunteer patients only, PSMA PET/CT is optional and not required).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2019</start_date>
  <completion_date type="Anticipated">October 17, 2031</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2030</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To define and document the biodistribution of gallium Ga 68 FAPi-46 (68Ga-FAPi-46) and gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) in normal and cancer tissues of patients with various non-prostate malignancies</measure>
    <time_frame>60 minutes after tracer injection</time_frame>
    <description>To quantify tumor tissue and normal background organs positron emission tomography (PET) tracer uptake by semi-quantitative analysis (unit/metrics = standardized uptake values (SUV)). The 68Ga-PSMA-11 and 68Ga-FAPI-46 tracer biodistribution will be described by mean and maximum standardized uptake values (SUVmean and SUVmax).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>68Ga-FAPi-46 and 68Ga-PSMA-11 accumulation</measure>
    <time_frame>From date of imaging to date of surgery (range 1-60 days)</time_frame>
    <description>To correlate PET imaging signal with fibroblast activation protein (FAP) and prostate specific membrane antigen (PSMA) expression by immunohistochemistry (IHC). 68Ga-FAPi-46 and 68Ga-PSMA tumor SUVs will be correlated with FAP and PSMA expression from surgically resected tumors. IHC will be scored with a semi-quantitative scoring system that accounts for staining intensity (0-2, where 0 is negative, 1 is weak, 2 is strong and eq. stands for equivocal). Correlations will be sought using least square regression analysis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Additional correlation of biodistribution of standard of care tracer</measure>
    <time_frame>60 minutes after tracer injection</time_frame>
    <description>68Ga-FAPI-46 biodistribution correlation with 68Ga-PSMA-11 and 18F-fluodeoxyglucose (FDG), if any FDG PET/CT has been performed as standard-of-care.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Breast Carcinoma</condition>
  <condition>Colon Carcinoma</condition>
  <condition>Esophageal Carcinoma</condition>
  <condition>Gastric Carcinoma</condition>
  <condition>Head and Neck Carcinoma</condition>
  <condition>Kidney Carcinoma</condition>
  <condition>Lung Carcinoma</condition>
  <condition>Ovarian Carcinoma</condition>
  <condition>Pancreatic Carcinoma</condition>
  <condition>Solid Neoplasm</condition>
  <condition>Uterine Corpus Cancer</condition>
  <arm_group>
    <arm_group_label>Basic Science (68Ga-FAPi-46 PET/CT, 68Ga-PSMA-11 PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 68Ga-FAPi-46 IV and undergo PET/CT scan over 20-50 minutes. Patients may also receive 68Ga-PSMA-11 IV and undergo PET/CT scan over 20-50 minutes on a separate day (for volunteer patients only, PSMA PET/CT is optional and not required).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo PET/CT scan</description>
    <arm_group_label>Basic Science (68Ga-FAPi-46 PET/CT, 68Ga-PSMA-11 PET/CT)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>computerized tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT scan</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Gallium Ga 68 FAPi-46</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Basic Science (68Ga-FAPi-46 PET/CT, 68Ga-PSMA-11 PET/CT)</arm_group_label>
    <other_name>68Ga-FAPi-46</other_name>
    <other_name>Gallium-68-FAPi-46</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Gallium Ga 68-labeled PSMA-11</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Basic Science (68Ga-FAPi-46 PET/CT, 68Ga-PSMA-11 PET/CT)</arm_group_label>
    <other_name>(68)Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Gallium-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68Ga)Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-DKFZ-PSMA-11</other_name>
    <other_name>68Ga-HBED-CC-PSMA</other_name>
    <other_name>68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-PSMA</other_name>
    <other_name>68Ga-PSMA-11</other_name>
    <other_name>68Ga-PSMA-HBED-CC</other_name>
    <other_name>[68Ga] Prostate-specific Membrane Antigen 11</other_name>
    <other_name>[68Ga]GaPSMA-11</other_name>
    <other_name>Ga PSMA</other_name>
    <other_name>Ga-68 labeled DKFZ-PSMA-11</other_name>
    <other_name>Ga-68 labeled PSMA-11</other_name>
    <other_name>Gallium Ga 68 PSMA-11</other_name>
    <other_name>Gallium-68 PSMA</other_name>
    <other_name>Gallium-68 PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>GaPSMA</other_name>
    <other_name>PSMA-HBED-CC GA-68</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET/CT scan</description>
    <arm_group_label>Basic Science (68Ga-FAPi-46 PET/CT, 68Ga-PSMA-11 PET/CT)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>positron emission tomography scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with the following cancer types:&#xD;
&#xD;
               -  Breast cancer&#xD;
&#xD;
               -  Colon cancer&#xD;
&#xD;
               -  Esophageal cancer&#xD;
&#xD;
               -  Gastric cancer&#xD;
&#xD;
               -  Head and Neck cancer&#xD;
&#xD;
               -  Lung cancer&#xD;
&#xD;
               -  Ovarian cancer&#xD;
&#xD;
               -  Pancreatic cancer&#xD;
&#xD;
               -  Renal cancer&#xD;
&#xD;
               -  Uterus cancer&#xD;
&#xD;
          -  Patients who are scheduled to undergo surgical resection of the primary tumor and/or&#xD;
             metastasis&#xD;
&#xD;
          -  Patient can provide written informed consent&#xD;
&#xD;
          -  Patient is capable of complying with study procedures&#xD;
&#xD;
          -  Patient is able to remain still for duration of imaging procedure (up to one hour)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is pregnant or nursing&#xD;
&#xD;
          -  Patient has underlying disease which based on the judgment of the investigator, might&#xD;
             interfere with the collection of high quality data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremie Calais, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA / Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Lira</last_name>
    <phone>310 206-7372</phone>
    <email>StephanieLira@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rejah Alano</last_name>
    <phone>310 206-7372</phone>
    <email>RMAlano@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiara Booker Adame</last_name>
      <phone>310-206-7372</phone>
      <email>KMBooker@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Lira</last_name>
      <phone>310 206-7372</phone>
      <email>StephanieLira@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jeremie Calais, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 24, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edetic Acid</mesh_term>
    <mesh_term>Gallium 68 PSMA-11</mesh_term>
    <mesh_term>FAPI-46</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

